What does this research mean for the field?

Nitroimidazole-based hypoxia-targeting strategies consistently enhance radiation response in preclinical models, although their clinical efficacy and translation remain heterogeneous. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate recent evidence on hypoxia-targeting strategies and nitroimidazole-based radiosensitizers combined with radiotherapy across preclinical, computational, and clinical studies.

August 27, 2026Current Issues in Molecular BiologyOpen Access

Hypoxia-Targeting Strategies in Radiotherapy and Nitroimidazole-Based Radiosensitizers: A Narrative Review and Translational Perspectives

View Full Paper

Ask AI

Bookmark

Authors

EREnrico RosaUniversità Cattolica del Sacro Cuore BFBruno FiondaAgostino Gemelli University Polyclinic MVMaria VaccaroAgostino Gemelli University Polyclinic

Discussion

Member takes

Implication

Narrative review reveals consistent preclinical radiosensitization by nitroimidazoles in hypoxic tumors, indicating promise despite variable clinical outcomes.

Key Points

To evaluate recent evidence on hypoxia-targeting strategies and nitroimidazole-based radiosensitizers combined with radiotherapy across preclinical, computational, and clinical studies.
Conducted a structured narrative review searching PubMed and Scopus in March 2026 for studies published within the last five years.
Included 16 studies evaluating hypoxia-targeting compounds and dose–response relationships across in vitro, in vivo, computational, and clinical settings.
Nitroimidazole-based strategies enhanced radiation response in hypoxic conditions, with sensitizer enhancement ratio values ranging from approximately 1.09 to 1.65.
In vivo tumor models demonstrated reductions in tumor volume and growth when treated with radiosensitizers plus radiotherapy, while clinical studies in head and neck squamous cell carcinoma showed variable locoregional outcomes.

Cite This Study

Rosa et al. (2026) studied this question.

synapsesocial.com/papers/6a8fe9b910c91c1e92621950 https://doi.org/10.3390/cimb48090863

View Full Paper

Ask AI

Bookmark

Implication

Narrative review reveals consistent preclinical radiosensitization by nitroimidazoles in hypoxic tumors, indicating promise despite variable clinical outcomes.

Hypoxia-Targeting Strategies in Radiotherapy and Nitroimidazole-Based Radiosensitizers: A Narrative Review and Translational Perspectives

Discussion

Member takes

Implication

Key Points

Cite This Study

Hypoxia-Targeting Strategies in Radiotherapy and Nitroimidazole-Based Radiosensitizers: A Narrative Review and Translational Perspectives

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider